Proxy Results Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Election of Class II Directors

On November 27, 2024, Actinium Pharmaceuticals, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). As previously reported in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 5, 2024 (the "Proxy Statement"), the term of each of the Company's Class II directors was scheduled to expire at the Annual Meeting, and the Company's board of directors (the "Board") nominated each director for re-election at the Annual Meeting.

At the Annual Meeting, each of Sandesh Seth and Jeffrey W. Chell was elected as a Class II director of the Board to serve for a term expiring at the Company's 2027 annual meeting of stockholders.